Register for email alerts and news feeds:
This journal | BMJ Group
rss
Evidence-Based Mental Health 2006;9:42; doi:10.1136/ebmh.9.2.42
Copyright © 2006 by BMJ Publishing Group Ltd, Royal College of Psychiatrists, & British Psychological Society.

Therapeutics

Olanzapine plus fluoxetine reduce depressive symptoms faster than either drug alone in people with treatment resistant depression

Shelton RC, Williamson DJ, Corya SA, et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry 2005;66:1289–97.[Medline]

Q Does a combination of olanzapine and fluoxetine lead to a greater reduction in symptoms in people with treatment resistant depression compared with either drug alone?

Key Words: olanzapine • fluoxetine • depression

The first 150 words of the full text of this article appear below.

METHODS

Formula Design: Multicentre randomised controlled trial.

Formula Allocation: Unclear.

Formula Blinding: Double blind.

Formula Follow up period: Eight weeks.

Formula Setting: Seventy one sites in the United States and Canada; study started in August 1999.

Formula Patients: 500 people (age 18–65 years) with treatment resistant unipolar, non-psychotic, major depression disorder (DSM-IV; Montgomery-Åsberg Depression Rating Scale (MADRS) total score >=20). Participants had not responded to a selective serotonin reuptake inhibitor in the past, and also failed to respond to nortriptyline (<30% reduction in MADRS score) during a seven week lead-in phase. Exclusions: inability to maintain adequate blood nortriptyline levels, taking medications with primary CNS activity (except lorazepam), receiving or likely to need electroconvulsive therapy, psychotic symptoms, and pregnant or lactating women.

Formula Intervention: Olanzapine (6–12 mg/day) plus fluoxetine (25–50 mg/day), olanzapine (6–12 mg/day) alone, fluoxetine (25–50 mg/day) alone, or nortriptyline (25–175 mg/day) alone.

Formula Outcomes: Mean change in MADRS score from baseline.

Formula Patient follow up: 80.4%.

MAIN RESULTS

At eight weeks, . . . [Full text of this article]

Seetal Dodd, PhD, Michael Berk, MD PhD

University of Melbourne, Geelong, Australia


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Online Education

Psychiatry CPD/CME from The Royal College of Psychiatrists

Professional Development from The British Psychological Society